Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

pituitary gigantism - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

pituitary gigantism

MONDO:0020479

Also known as:hypophyseal gigantisminfantile and juvenile forms of acromegalygigantism

Find Clinical TrialsTrials

Overview

The condition of accelerated and excessive growth in children or adolescents who are exposed to excess human growth hormone before the closure of epiphyses. It is usually caused by somatotroph hyperplasia or a growth hormone-secreting pituitary adenoma. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.

Treatments1 FDA approved

Clinical Trials3 registered · 3 recruiting

Diagnosis

Biomarker and diagnostic research for pituitary gigantism has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for pituitary gigantism, including ARGININE HYDROCHLORIDE (R-GENE, approved 1973).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

3 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE3. Research is sponsored by a mix of industry and academic institutions.

125 publications have been identified in PubMed for pituitary gigantism. Research spans Basic Science / Preclinical (53%), Review / Meta-Analysis (18%), and Case Report / Case Series (17%).

Research Type	Count	% of Total
Laboratory research	66

Data assembled from 5 of 12 sources · Last updated Oct 3, 2026, 1:49 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:99725

GARD

Genetic and Rare Diseases Info Center

GARD:6506

Questions for Your Care Team

→What are the benefits and potential side effects of R-GENE for managing pituitary gigantism?
→Are any of the 3 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

pituitary gigantism

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications